Nkarta
$2.4
39
+$0.08+3.23% Today
Statistics
Day High
2.43
Day Low
2.31
52W High
2.81
52W Low
1.42
Volume
135,281
Avg. Volume
765,438
Mkt Cap
170.12M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
7MayExpected
Expected EPS
-0.358
Actual EPS
N/A
Financials
-Profit Margin
Unprofitable0Revenue
-217.58MNet Income
Analyst Ratings
$11.33Average Price Target
The highest estimate is 12.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow NKTX. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Fate Therapeutics
FATE
Mkt Cap141.84M
CRISPR Therapeutics
CRSP
Mkt Cap4.75B
Allogene Therapeutics
ALLO
Mkt Cap604.57M
Gilead Sciences
GILD
Mkt Cap173.41B
Novartis
NVS
Mkt Cap297.32B
Precigen
PGEN
Mkt Cap1.39B
About
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Show more...
CEO
Mr. Paul J. Hastings
Employees
157
Country
US
ISIN
US65487U1088
Listings
0 Comments
Share your thoughts
FAQ
What is Nkarta stock price today?▼
The current price of NKTX is $2.4 USD — it has increased by +3.23% in the past 24 hours. Watch Nkarta stock price performance more closely on the chart.
What is Nkarta stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Nkarta stocks are traded under the ticker NKTX.
Is Nkarta stock price growing?▼
NKTX stock has risen by +20% compared to the previous week, the month change is a -4% fall, over the last year Nkarta has showed a +47.24% increase.
What is Nkarta market cap?▼
Today Nkarta has the market capitalization of 170.12M
When is the next Nkarta earnings date?▼
Nkarta is going to release the next earnings report on May 07, 2026.
What were Nkarta earnings last quarter?▼
NKTX earnings for the last quarter are -0.29 USD per share, whereas the estimation was -0.3 USD resulting in a +4.89% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Nkarta revenue for the last year?▼
Nkarta revenue for the last year amounts to 0 USD.
What is Nkarta net income for the last year?▼
NKTX net income for the last year is -217.58M USD.
How many employees does Nkarta have?▼
As of April 06, 2026, the company has 157 employees.
In which sector is Nkarta located?▼
Nkarta operates in the Health Care sector.
When did Nkarta complete a stock split?▼
Nkarta has not had any recent stock splits.
Where is Nkarta headquartered?▼
Nkarta is headquartered in South San Francisco, US.